Ticker League

EBITDA for Gilead Sciences (GILD)

Latest filings through · Reported

Metric

TTM

$13.33B

YoY change

+206.3%

5Y CAGR

+26.9%

Peak year (2015)

$23.45B

EBITDA history chart for Gilead Sciences (GILD) from 1990 to 2025

Latest: $13.58B

EBITDA growth chart for Gilead Sciences (GILD) from 1990 to 2025

Latest: +206.3%

EBITDA history table for Gilead Sciences (GILD) from 1990 to 2025

  • 2025$13.58B+206.3%
  • 2024$4.43B-57.8%
  • 2023$10.50B+18.6%
  • 2022$8.85B-21.9%
  • 2021$11.33B+174.1%
  • 2020$4.13B-45.3%
  • 2019$7.56B-26.6%
  • 2018$10.30B-35.3%
  • 2017$15.93B-17.1%
  • 2016$19.22B-18.0%
  • 2015$23.45B+43.7%
  • 2014$16.32B+235.8%
  • 2013$4.86B+14.3%
  • 2012$4.25B+2.2%
  • 2011$4.16B-3.0%
  • 2010$4.29B+13.3%
  • 2009$3.78B+30.8%
  • 2008$2.89B+30.6%
  • 2007$2.22B+31.7%
  • 2006$1.68B+47.0%
  • 2005$1.14B+75.6%
  • 2004$651.79M+85.8%
  • 2003$350.78M+267.6%
  • 2002$95.44M-190.0%
  • 2001−$106.00M+163.0%
  • 2000−$40.31M+3.1%
  • 1999−$39.10M-39.9%
  • 1998−$65.10M+14.4%
  • 1997−$56.90M+80.1%
  • 1996−$31.60M+9.7%
  • 1995−$28.80M-8.0%
  • 1994−$31.30M—
  • 1992−$16.50M+211.3%
  • 1991−$5.30M+32.5%
  • 1990−$4.00M—

EBITDA values are taken from Gilead Sciences's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About EBITDA at Gilead Sciences (GILD)

According to Gilead Sciences's latest reported financial statements, the company's current EBITDA (TTM) is $13.33B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.

Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .

Gilead Sciences (GILD) most recent annual EBITDA stands at $13.58B (2025) – surged 206.3% year-over-year.

Across 2020–2025 (5 years), Gilead Sciences EBITDA produced a CAGR of +26.9% – with mixed annual results across the window.

Gilead Sciences EBITDA peaked at $23.45B in 2015; the latest annual figure is $13.58B in 2025 (42.1% below peak).

2015 marks the peak EBITDA at $23.45B, with the historical low of −$106.00M recorded in 2001.

Gilead Sciences EBITDA by Year

Gilead Sciences EBITDA 2025: $13.58B

2025's EBITDA for Gilead Sciences came in at $13.58B, surged 206.3% from 2024.

Gilead Sciences EBITDA 2024: $4.43B

Gilead Sciences posted EBITDA of $4.43B in 2024, plunged 57.8% below 2023.

Gilead Sciences EBITDA 2023: $10.50B

In 2023, Gilead Sciences reported EBITDA of $10.50B, grew 18.6% from 2022.

Gilead Sciences EBITDA 2022: $8.85B

Gilead Sciences EBITDA in 2022 was $8.85B, declined 21.9% below 2021.

Gilead Sciences EBITDA 2021: $11.33B

Gilead Sciences EBITDA in 2021 was $11.33B.

See more financial history for Gilead Sciences (GILD).

Sector peers by EBITDA

Healthcare peers of Gilead Sciences (GILD), ranked by their latest EBITDA

Frequently asked questions

Gilead Sciences (GILD) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation